There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive
- PMID: 30188787
- DOI: 10.1200/JCO.2018.79.3166
There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive
Comment in
-
Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.J Clin Oncol. 2018 Oct 20;36(30):3064-3065. doi: 10.1200/JCO.2018.79.3190. Epub 2018 Sep 6. J Clin Oncol. 2018. PMID: 30188784 No abstract available.
-
Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.J Clin Oncol. 2018 Oct 20;36(30):3065-3066. doi: 10.1200/JCO.2018.79.3208. Epub 2018 Sep 6. J Clin Oncol. 2018. PMID: 30188791 No abstract available.
Comment on
-
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28. J Clin Oncol. 2018. PMID: 29590007 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
